The incidence and prevalence of neurodegenerative diseases (ND) increase with life expectancy. This paper reviews the role of oxidative stress (OS) in ND and pharmacological attempts to fight against reactive oxygen species (ROS)-induced neurodegeneration. Several mechanisms involved in ROS generation in neurodegeneration have been proposed. Recent articles about molecular pathways involved in ROS generation were reviewed. The progress in the development of neuroprotective therapies has been hampered because it is difficult to define targets for treatment and determine what should be considered as neuroprotective. Therefore, the attention was focused on researches about pharmacological targets that could protect neurons against OS. Since it is necessary to look for genes as the ultimate controllers of all biological processes, this paper also tried to identify gerontogenes involved in OS and neurodegeneration. Since neurons depend on glial cells to survive, recent articles about the functioning of these cells in aging and ND were also reviewed. Finally, clinical trials testing potential neuroprotective agents were critically reviewed. Although several potential drugs have been screened inin vitroandin vivomodels of ND, these results were not translated in benefit of patients, and disappointing results were obtained in the majority of clinical trials.

Zanthoxylum tinguassuiba essential oil (ZtEO) contains α-bisabolol, a known antiglioma sesquiterpene, among other potentially active substances. Medical applications of this essential oil require advances in the design of distinctive carriers due to its low water solubility and easy degradation by heat, light, and oxygen. The aim of this work was to evaluate enhancement in oxidative stability and the ability to reduce glioblastoma cell viability of ZtEO loaded into liposomes. Multi- and unilamellar vesicles were prepared to carry ZtEO. By using thermal analysis, it was observed that thermal-oxidative stability of the liposomal ZtEO was enhanced, when compared to its free form. Liposomal ZtEO also presented significant apoptotic-inducing activity for glioma cells. These results show that liposomal systems carrying ZtEO may be a potential alternative for gliobastoma treatment.